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Abstract
OBJECTIVE: To explore the effect of electroacu-
puncture and Chinese kidney-nourishing medicine
on insulin (INS), adiponectin (APN), leptin (LEP),
and glucolipid metabolism of obese patients with
polycystic ovary syndrome (PCOS).
METHODS: Sixty-seven obese PCOS patients were
randomly divided into two groups. Thirty-three pa-
tients in the acupuncture-medicine group were
treated three times a week with electroacupunc-
ture at the Tianshu (ST 25), Zhongwan (CV 12), Qi-
hai (CV 6), Sanyinjiao (SP 6), Geshu (BL 17), and Cil-
iao (BL 32) acupoints. They also took the Chinese
drug, Tiankui capsule, for 3 months as a course of
treatment. Point-taking and treatment in the elec-
troacupuncture group of 34 patients was the same
as those in the acupuncture-medicine group. We
observed and compared the changes in the obesi-
ty-related indexes of body weight (BW), body mass
index (BMI), and waist-hip ratio (WHR), as well as
fasting plasma glucose (FPG), fasting insulin (FINS),
APN, and LEP.
RESULTS: BW, BMI, WHR, and FINS decreased and
insulin sensitivity index (ISI) and APN were higher
in the acupuncture-medicine group than in the
electroacupuncture group (P<0.01). There was no
obvious difference in LEP between the two groups
(P>0.05).
CONCLUSION: Acupuncture combined with medi-
cine is better than just electroacupuncture for
obese PCOS patients by improving obesity-related
indexes, insulin sensitivity, and APN level. This indi-
cates that acupuncture-medicine therapy is worth
clinical popularization.
© 2013 JTCM. All rights reserved.
Key words: Electroacupuncture; Reinforcing kid-
ney; Polycystic ovary syndrome; Obesity; Insulin;
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common gyne-
cological disease with reproductive dysfunction, endo-
crine disorder, and abnormal glucolipid metabolism. It
287
JTCM |www. journaltcm. com June 15, 2013 |Volume 33 | Issue 3 |
Yu LQ et al. / Clinical Study
is characterized by complex causes of disease and diver-
sified clinical manifestations. PCOS, the main cause
for menstrual disorder and infertility in women of
childbearing age, is manifests clinically as oligomenor-
rhea or amenorrhea, infertility, obesity, hirsutism, acne,
or psychosis. Obesity, the most common complication
of PCOS, is the driving force and cause of other meta-
bolic diseases. More than 50% of PCOS patients are
overweight or obese1 and most suffer from central (ab-
dominal) obesity. Patients with abdominal obesity easi-
ly contract glucolipid metabolic disorder and cardioce-
rebrovascular diseases. Moreover, the endocrine func-
tion of female patients is more easily affected. Obesity
can promote PCOS and eventually disrupt endocrine
and metabolic function.2 Appropriately reducing the
body weight of obese PCOS patients can improve en-
docrine disorder to restore ovulatory function.3 There-
fore, the key to treatment of obese PCOS patients lies
in finding a way to reduce obesity, and improve lipid
metabolism and endocrine disorder.
Basedon the curative effects ofChinesemedicine and acu-
puncture onobesity andPCOS inprevious research,4-6 we
compared electroacupuncture combined with Chinese
kidney-nourishing medicine (Tiankui capsule) with
normal electroacupuncture. We observed their effects
on obese indexes, insulin sensitivity, adiponectin,
leptin, and other lipid metabolism measures in obese
PCOS patients and explored the mechanism.
METHODS
General data
Sixty-seven patients at a PCOS clinic in the Shanghai
Institute of Acupuncture, Moxibustion and Meridians
from July 2010 to December 2011 were randomly di-
vided into two groups. The age of the 33 patients in
the acupuncture-medicine group was 17-39 years and
(25±6) years on average. Their illness course was 1-20
years and (7 ± 4) years on average. Their body weight
was 60-95 kg and (76±9) kg on average. The age of the
34 patients in the electroacupuncture group was 17-37
years and (25±5) years on average. Their illness course
was 1-20 years and (7±4) years on average. Their body
weight was 64-99 kg and (77±9) kg on average. There
was no statistical difference in general data between the
two groups (P>0.05).
Diagnostic standards
Diagnostic standards in Western Medicine: PCOS was
diagnosed according to the Rotterdam criteria issued
by the European Human Reproduction and Embryolo-
gy Research Center and the American Society for Re-
productive Medicine in January 2003.7 Patients con-
forming to two of the following indexes were diag-
nosed as suffering from PCOS: (a) oligoovulation or
no ovulation, (b) clinical manifestations of hyperandro-
genemia and (or) hyperandrogenism (such as hirsutism
and acne), and (c) ≥12 small follicles, 2-9 mm in diam-
eter, in both ovaries, and (or) ovarian volume ≥10 mL.
Patients with congenital adrenal hyperplasia, thyroid
disease, androgen secreting tumors, or Cushing's syn-
drome were excluded.
Obesity was diagnosed according to the Asian adult
obese index of Body Mass Index (BMI) ≥25 stipulated
by WHO in 2000. BMI=body weight (kg)/height (m)2.
Syndrome differentiation in Traditional Chinese Medi-
cine (TCM): All patients have kidney deficiency with
phlegm blockage and blood stasis or damp-heat accu-
mulation.
The main symptoms are obesity, oligomenorrhea or
amenorrhea, hirsutism, acne, lassitude in loin and
knee, cold limbs, dysphoria with a feverish sensation in
the palms and soles, dizziness, heaviness in the head,
oppressed feeling in the chest, nausea, somnolence, fa-
tigue, abdominal fullness, hypochondral distension,
vexation, irritability, insomnia, dreaminess, poor appe-
tite, loose stool, constipation, red urine, leukorrhagia
or yellow thick and stench leucorrhea, a pale and en-
larged tongue with thick and yellow coating, and a
sunken, thready and slippery pulse.
Standards for inclusion: (a) Patients conforming to
PCOS diagnostic criteria in Western Medicine and syn-
drome differentiation in TCM. (b) Patients with no
secondary PCOS, namely, no other systemic diseases.
(c) Female patients 14-45 years old. (d) Patients accept-
ing no other treatments 3 months before treatment
and during treatment. (e) Patients voluntarily partici-
pating in the study and signing a participation release
agreement passed by the ethical evaluation of Yueyang
Hospital of TCM Combined with Western Medicine
affiliated to Shanghai University of TCM.
Standards for exclusion
(a) Patients with congenital adrenal hyperplasia, thy-
roid disease, androgen secreting tumors, and Cushing's
syndrome. (b) Patients suffering from other serious dis-
eases (cardiocerebrovascular diseases, damage to the
function of liver and kidney, and mental illness). (c) Pa-
tients taking hormonal and metabolic drugs affecting
the judgment of results. (d) Patients unable to tolerate
or maintain treatment course.
Therapies
Acupuncture-medicine group:
Treatment with electroacupuncture: there were two
groups of main acupoints. Group I, included bilateral
acupoints Sanyinjiao (SP 6), Xuehai (SP 10), Zusanli
(ST 36), Tianshu (ST 25), Daheng (SP 15), Daimai
(GB 26), Dahe (KI 12), Zigong (EX-CA 1), Taixi (KI
3), Zhongwan (CV 12), Qihai (CV 6), and Guanyuan
(CV 4). Group II, included bilateral acupoints Sanyin-
jiao (SP 6), Taixi (KI 3), Yinlingquan (SP 9), Ganshu
(BL 18), Geshu (BL 17), Shenshu (BL 23), Pishu (BL
20), and Ciliao (BL 32).
The bilateral acupoints Hegu (LI 4), Gongsun (SP 4),
Fenglong (ST 40) and Diji (SP 8) were added for
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phlegm blockage and blood stasis. Bilateral acupoints
Zhigou (TE 6), Quchi (LI 11), Taichong (LR 3), and
Yanglingquan (GB 34) were added for damp-heat accu-
mulation.
For treatment with electroacupuncture, needles,
0.28-0.32 mm in diameter and 40-75 mm in length,
were inserted into acupoints with the uniform reinforc-
ing-reducing method. After needling sensation, needles
at the bilateral acupoints Tianshu (ST 25), Sanyinjiao
(SP 6), Zhongwan (CV 12), and Qihai (CV 6), or bi-
lateral acupoints Pishu (BL 20), Shenshu (BL 23), Cil-
iao (BL 32), and Sanyinjiao (SP 6) were connected to a
G6805II electric stimulator with continuous wave, 2
HZ frequency and an electrical current tolerable to pa-
tients. The needle was retained for 40 min. The rest of
the acupoints were manipulated once every 10 min.
Acupuncture was performed 3 times a week for a men-
strual cycle or a month as a course of treatment. After
three courses of treatment, the therapeutic effect was
observed.
Treatment with Chinese medicine: Tiankui capsule, de-
veloped by Obstetric and Gynecological Hospital affili-
ated to Fudan University, consists of Dihuang (Radix
Rehmanniae), Zhimu (Rhizoma Anemarrhenae), Xian-
lingpi (Herba Epimedium), Huzhang (Polygonum Cuspi-
datum), Mabiancao (Verbenae), Danggui (Radix Angeli-
cae Sinensis), Taoren (Semen Persicae), Huangjing (Rhi-
zoma Polygonati), Shichangpu (Rhizoma Acori Gramin-
ei), Guiban (Carapax et Plastrum Testudinis), and Bugu-
zhi (Fructus Psoraleae). Tiankui Capsule was orally tak-
en, six capsules a time, in the morning and evening, for
three months.
Electroacupuncture group: Acupoint selection, manipu-
lation, and treatment course were the same as in the
acupuncture-medicine group.
Indexes and methods for observation
The indexes of Body Weight (BW), Body Mass Index
(BMI), and Waist Hip Rate (WHR) were observed be-
fore and after treatment in the two groups. BMI=
weight (kg)/height (m)2. WHR=WC/HC. WC is waist
circumference (cm) at the navel when the patient is up-
right. HC is hip circumference (cm) around the hip
femoral trochanter.
Fasting insulin (FINS) and fasting plasma glucose
(FPG) in the serum were observed before and after
treatment in the two groups. FINS was determined
with a radioimmunoassay kit from Beijing North Bio-
technology Institute. FPG was determined with a glu-
cose assay kit from Shanghai Rongsheng Biotechnolo-
gy Co., Ltd. (Shanghai, China).
Adiponectin (APN) level in the serum was observed be-
fore and after treatment in the two groups. APN was
determined with a human adiponectin enzyme-linked
immuno sorbent assay (ELISA) assay kit from Ameri-
can RD Company (Minneapolis, MN, USA).
Leptin (LEP) level in the serum was observed before
and after treatment in the two groups. LEP level was
determined with a human leptin ELISA kit from Amer-
ican RD Company American R&D Systems Inc. (Min-
neapolis, MN, USA).
Statistical analysis
SPSS 15.0 statistical software (SPSS Inc., Wacker
Drive, Chicago, IL, USA) was used. Measurement data
conforming to a normal distribution are expressed with
mean±standard deviation( xˉ ±s). Measurement data not
conforming to a normal distribution are expressed with
the median (QL－QU). Group t-test was used for the dif-
ference between the two groups. Paired t-test was used
for the difference before and after treatment in the
same group. A non-parameter test was used for data




During observation, two patients withdrew from the
electroacupuncture group and were ultimately exclud-
ed from statistics. No patients withdrew from the acu-
puncture-medicine group.
Comparison of BW, BMI, and WHR before and
after treatment
Table 1 shows that there was a statistical difference (P<
0.01) in BW, BMI, and WHR before and after treat-
ment in the acupuncture-medicine group and in BW
and BMI in the electroacupuncture group (P<0.05).
The BW, BMI, and WHR in the acupuncture-medi-
cine group were lower than those in the electroacu-
puncture group (P<0.01, P<0.01, and P<0.05, respec-
tively).
Comparison of FPG, FINS, and ISI before and after
treatment
Table 2 shows that there was a statistical difference (P<
0.01) in FPG, FINS, and ISI before and after treat-
ment in the acupuncture-medicine group. There was
no statistical difference (P>0.05) in FINS and ISI be-
fore and after treatment in the electroacupuncture
group. FINS, and ISI improved more in the acupunc-
ture-medicine than the electroacupuncture group (P<
0.01). No statistical difference was found in FPG be-
tween the two groups (P>0.05).
Comparison of APN and LEP before and after
treatment
There was a much higher APN after treatment in the
acupuncture-medicine (P<0.01) and electroacupunc-
ture groups (P<0.05) (Table 3). There was no obvious
difference (P>0.05) in LEP before and after treatment
in the two groups.
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DISCUSSION
Obese PCOS is clinically characterized by reproductive
dysfunction, endocrine disorder, and abnormal gluco-
lipid metabolism. In recent years, lifestyle changes and
stress have raised its incidence to 7%-8% in women of
childbearing age.8 The complex pathogenesis of PCOS
and lack of precise theoretical basis for its pathogenic
hypotheses make effective therapy difficult to develop.
Clinical and experimental research have discovered that
PCOS affects women's fertility and is closely related to
type II diabetes, hyperlipemia, hypertension, cardiovas-
cular disease and metabolic syndrome, and possibly in-
creases the risk of contracting endometrial carcinoma
and breast cancer. Of PCOS patients, 50%-70% are
overweight or obese making obesity the most common
symptom. Most patients exhibit abdominal obesity.1
PCOS patients with abdominal obesity often have glu-
colipid metabolism disorders, which lead to reproduc-
tive problems and aggravate the ovaries to promote the
development of PCOS. Therefore, obese PCOS pa-
tients are more likely to have relevant clinical symp-
toms than those who are not obese. Western treatment
of PCOS can promote ovulation, normalize endocrine
metabolism, and improve clinical symptoms. However,
drug dependence or relapse after disuse of drugs and
toxic side effects of oral medication greatly limit the
clinical use of Western Medicine. TCM including acu-
puncture can have certain curative effects on PCOS.
However, it takes longer for Chinese medicine or acu-
puncture to take effect than Western Medicine in the
treatment of PCOS. Therefore, is difficult for patients
to persist on treatment because of its slow effect and
potential for relapse. Nevertheless, acupuncture com-
bined with Chinese medicine has advantages over each
alone. The Handbook of Prescription for Emergencies
states that,“Those who apply acupuncture without
moxibustion or moxibustion without acupuncture are
not good doctors. Those who apply acupuncture with-
out medicine or medicine without acupuncture are es-
pecially not good doctors. Those who know both medi-
cine and acupuncture are good doctors.”Therefore, ex-
ploring whether acupuncture plus medicine takes effect
more quickly with fewer side effects than each alone is
important in directing the clinical treatment of obese
PCOS.
According to its clinical manifestations, PCOS can be
attributed to "amenorrhea," "infertility," "masses in the
abdomen," or "obesity" in TCM. Obese PCOS pa-
tients often have kidney deficiency and phlegm-damp-
ness constitutions. A deficiency of kidney essence
Group

























Notes: BW: body weight; BMI: body mass index; WHR: waist-hip ratio; PCOS: polycystic ovary syndrome. aP<0.01, cP<0.05, compared
with the datum before treatment in the same group; bP<0.01, dP<0.05, compared with the datum in the electroacupuncture group.
Table 1 Comparison of BW, BMI, andWHR before and after treatment ( xˉ ±s)
Group
Acupuncture combined with

























Table 2 Comparison of FPG, FINS, and ISI before and after treatment ( xˉ ±s)
Notes: FPG: fasting plasma glucose; FINS: fasting insulin; ISI: insulin sensitivity index; PCOS: polycystic ovary syndrome. aP<0.01,
compared with the datum before treatment in the same group; bP<0.01, compared with the datum in the electroacupuncture group.
Group




















Table 3 Comparison of APN and LEP before and after treatment ( xˉ ±s)
Notes: PCOS: polycystic ovary syndrome; APN: adiponectin; LEP: leptin. aP<0.01, cP<0.05, compared with the datum before treatment
in the same group; bP<0.05, compared with the datum in the electroacupuncture group.
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makes it difficult for the ovum to develop. A deficiency
of kidney Yang cannot warm spleen Yang, causing an
obstructed circulation of Qi and blood and making wa-
ter accumulate into phlegm. A deficiency of kid-
ney-Yin cannot nourish the uterus, causing fewer men-
ses.9 Phlegm-dampness is not only the metabolic prod-
uct of spleen deficiency and kidney deficiency, but also
the cause of Qi stagnation. The stagnation of
phlegm-dampness causes a rough flow of Qi and a dis-
order of Qi transformation in triple energizer. Prescrip-
tion for Saving Lives says that a "Blockage of Qi in tri-
ple energizer and obstruction of vessels make water ac-
cumulate into phlegm, leading to various diseases."
This situation further causes imbalance of Yin and
Yang. Stagnation of Qi, blood, and phlegm-dampness
in the Chong and conception vessels make it difficult
for the ovum to be discharged, causing oligomenor-
rhea, amenorrhea, and infertility. Stagnation of
phlegm-dampness causes rough circulation of Qi and
blood, forming masses in the abdomen and polycystic
ovaries. The pathogenesis for obese PCOS mainly lies
in kidney deficiency and stagnation of phlegm-damp-
ness in the uterus. Therefore, this disease should be
treated mainly by nourishing kidney, strengthening
spleen, dissolving phlegm, and removing dampness. In
addition, treatment should soothe liver and promote
blood circulation.10-12 Tiankui capsule can nourish kid-
ney, strengthen spleen, remove dampness, dissolve
phlegm, promote blood circulation, and eliminate
blood stasis. The ingredients Xianlingpi (Herba Epime-
dium), Huangjing (Rhizoma Polygonati), Buguzhi (Fruc-
tus Psoraleae), and Guiban (Carapax et Plastrum Testudi-
nis) can warm and nourish kidney Yang, enrich kid-
ney-Yin, and regulate the Chong and conception ves-
sels. These ingredients have a similar effect as sex hor-
mones and can promote gonadal (ovarian) function.
The adjunct ingredients Danggui (Radix Angelicae Si-
nensis), Taoren (Semen Persicae), Dihuang (Radix Rehm-
anniae), Zhimu (Rhizoma Anemarrhenae), Huzhang
(Polygonum Cuspidatum), Mabiancao (Verbena), and
Shichangpu (Rhizoma Acori Graminei) can promote
blood circulation, regulate menstruation, regulate Qi
flow, generate blood, clear away heat, eliminate swell-
ing, dissolve phlegm, remove blood stasis, lower blood
glucose and lipids, and regulate uterine function.
Tiankui capsule can promote microcirculation and en-
docrine function of the ovary and improve glucolipid
metabolism of obese PCOS patients.13-15 lectro-acu-
puncture at Zhongwan (CV 12), Qihai (CV 6), and
Guanyuan (CV 4) can regulate the Chong and concep-
tion vessels, warm kidney Yang, and generate blood.
Electro-acupuncture at Taixi (KI 3) and Dahe (KI 12)
can nourish kidney-essence to regulate menstruation.
Electro-acupuncture at Sanyinjiao (SP 6) can dredge
the channels of the kidney, liver, and spleen. Elec-
tro-acupuncture at Xuehai (SP 10), Daheng (SP 15)
and Yinlingquan (SP 9) can invigorate spleen, remove
dampness, and dissolve phlegm. Electro-acupuncture
at Zusanli (ST 36) and Tianshu (ST 25) can regulate
Qi flow, remove dampness, dissolve phlegm and reduce
lipids. Electro-acupuncture at Daimai (GB 26) can reg-
ulate all channels. Electro-acupuncture at Zigong
(EX-CA1) can enrich Qi and blood, promote ovula-
tion, and regulate menstruation. Electro-acupuncture
at Ganshu (BL 18), Geshu (BL 17), Shenshu (BL 23),
Pishu (BL 20), and Ciliao (BL 32) can regulate func-
tional activities of Qi in internal organs. In addition to
the main acupoints, Hegu (LI 4), Gongsun (SP 4), Fen-
glong (ST 40), and Diji (SP 8) can be added for
phlegm stagnation and blood stasis to further strength-
en the effect of dissolving phlegm and removing blood
stasis. Zhigou (TE 6), Quchi (LI 11), Taichong (LR 3),
and Yanglingquan (GB 34) can be added for
damp-heat accumulation to soothe liver and clear col-
laterals. All these acupoints used together can enrich
kidney essence, regulate the Chong and conception ves-
sels, and nourish the uterus. In this study, we found
that Chinese medicine plus electroacupuncture can reg-
ulate Yin, Yang, Qi, and blood; normalize kidney func-
tion, the Chong and conception vessels, and the uterus;
promote ovarian micro-circulation and endocrine func-
tion; improve glucolipid metabolism; and reduce the
body weight of obese PCOS patients.
Obese PCOS patients often have insulin resistance
(IR) and hyperinsulinemia (HI). Insulin resistance, par-
ticularly ovarian local IR, will cause hyperandrogenism
and inhibit follicular maturation.16 HI inhibits the syn-
thesis of liver sex hormones and globulin, promotes the
biological activity of free testosterone and inhibits fol-
licular maturation to cause infertility.17 IR is a very im-
portant link in the development of obese PCOS. APN
is closely related to IR and has an important influence
on IR pathogenesis of obese PCOS. APN is a new
method to treat obese PCOS and probe its pathogene-
sis. APN, a plasma protein secreted by adipose tissue,
can affect the metabolism of blood glucose and lipids,
promote the transformation of preadipocytes into ma-
ture adipocytes, enhance insulin sensitivity, eliminate
inflammation, resist atherosclerosis, and plays an impor-
tant role in the occurrence and development of IR.18,19
APN has an antagonistic effect on IR.20 The normal
concentration of APN in non-obese healthy patients is
5-30 μg/mL. An increase in lipids will cause a decrease
in APN to increase body weight.21,22 Obesity23-27 and its
related diseases (PCOS28-30 and type II diabetes31) re-
duce APN in the plasma. Therefore, the lower the
APN level in obese PCOS patients, the more severe the
IR and clinical symptoms.32 This study shows that BW,
BMI, and WHR improvement is followed by a de-
crease in serum FINS level and a significant increase in
ISI and APN levels, when treated with electroacupunc-
ture plus medicine. However, the relationship between
APN and IR in the pathogenesis of obese PCOS needs
to be studied further. This study suggests that acupunc-
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ture plus medicine can increase APN level and reduce
insulin resistance in obese PCOS patients to improve
signs of abdominal obesity and abnormal glucolipid
metabolism.
Leptin (LEP), a protein hormone secreted by fat cells,
is encoded by the obese (OB) gene. In addition to regu-
lating diet and metabolism, LEP may stimulate the se-
cretion of growth hormone, prolactin, and other anteri-
or pituitary hormones.33,34 This influences the synthesis
and secretion of insulin and steroid hormones, leading
to obesity, reproductive dysfunction, and metabolic dis-
order.35-37 However, there are different opinions on the
relationship of LEP to obesity and PCOS. Once the
sensitivity of visceral lipids to insulin declines, lipids
are easily decomposed by LEP to create IR.38 However,
others39-42 believe that an increase in LEP may not be
closely related to PCOS and is just a factor that influ-
ences obesity. An increase in LEP levels of obese PCOS
patients may result from obesity. The results of this
study show that with an improvement in obesity-relat-
ed indexes in obese PCOS patients, no obvious differ-
ence was observed in LEP levels before and after treat-
ment. This indicates that there is no direct relation be-
tween LEP and the pathogenesis of PCOS. The exact
relationship between LEP and obese PCOS is to be fur-
ther confirmed.
This study showed that the improvement of obesity-re-
lated indexes, insulin resistance, and adiponectin level
in the acupuncture-medicine group was better than
that in the electroacupuncture group in the treatment
of obese PCOS patients. Therefore, electroacupuncture
plus Chinese medicine might originate from the same
therapeutic principle. Both methods use TCM theo-
ries, methods, formulae and medicines (acupoints) to
stimulate the self-regulatory function of human body
and gradually normalize nerves, endocrine function,
lipid metabolism, and visceral functions. The results of
this study also suggest that acupuncture plus medicine
can provide more benefits than electroacupuncture
alone in the same course of treatment. Therefore, we
provided clinical data and a theoretical basis for the
treatment of obese PCOS with Chinese medicine and
acupuncture.
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